Kardigan, Inc. (KARD)
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Kardigan, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 93.50M shares outstanding
USKardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.
It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes.
The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Leadership
Donald Mackenzie
Chief Technical Operations Officer
Employees
241
Country
US
Sector
Healthcare
Website
kardigan.bio
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Reinke Kristin Marie K | Director | Grant/Award | 48.4K | -- | Sep 29, 2026 |
 HRTG GPE, LLC | 10% Owner | Purchase | 3.13M | $50.00M | Jun 22, 2026 |
 BERNS PAUL L | Director | Purchase | 1.25M | $20.00M | Jun 22, 2026 |
 ARCH Venture Partners XIII, LLC | Director | Purchase | 1.25M | $20.00M | Jun 22, 2026 |
| ARCH Venture Partners XIII, LLC | Director | Conversion of Derivative | 13.79M | -- | Jun 17, 2026 |
 Pasternak Andy | Chief Strategy Officer | Grant/Award | 79.6K | -- | Jun 17, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
HRTG GPE, LLC | 16.9M | 18.1% | 13F |
FMR LLC · also on 13F· joint filing· may incl. warrants· filed Aug 2026 | 9.2M | 9.9% | 13G |
FMR LLC | 8.9M | 9.5% | 13F |
Perceptive Advisors LLC · also on 13F· joint filing· may incl. warrants· filed Oct 2026 | 8.3M | 8.8% | 13D |
PERCEPTIVE ADVISORS LLC | 8.2M | 8.8% | 13F |
T. Rowe Price Investment Management, Inc. | 4.2M | 4.5% | 13F |
Capital Research Global Investors | 3.6M | 3.8% | 13F |
JPMORGAN CHASE & CO | 1.8M | 1.9% | 13F |
ALLIANCEBERNSTEIN L.P. | 1.5M | 1.6% | 13F |
Liberty Mutual Group Asset Management Inc. | 1.2M | 1.3% | 13F |
Insiders
- Reinke Kristin Marie KDirector
- HRTG GPE, LLC10% Owner
- BERNS PAUL LDirector
- ARCH Venture Partners XIII, LLCDirector
- Pasternak AndyChief Strategy Officer
- Meeker David PDirector
- Moriarty John BChief Legal Officer
- Jahn BrianneChief Financial Officer
- Popovits Kimberly JDirector
- Walbert Timothy PDirector
based on 93.50M shares outstanding
US30d Avg
639.55K
60d Avg
721.89K
90d Avg
542.90K